No such message found

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: ESPR got crushed today

http://www.acc.org/latest-in-cardiology/articles/2018/03/05/15/53/sat-9am-odyssey-outcomes-cv-outcomes-with-alirocumab-after-acs-acc-2018

It looks like diminishing returns but they were able to show a cv outcome benefit in this study.

Still room for RVX to work on residual risk.

The LDL hypothesis does not explain all cv risk.

 

bfw

Share
New Message
Please login to post a reply